Recent studies highlight the risks of semaglutide, a main ingredient in diabetes treatments, in increasing eye condition ...
Patients with diabetes who take semaglutide are at increased risk for NAION compared with patients who do not use GLP-1 RAs to control their blood sugar, a new study finds.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback